Efficacy and safety of prostate vaporesection using a 120-W 2-μm continuous-wave Tm:YAG laser (RevoLix 2) in patients on continuous oral anticoagulant or antiplatelet therapy.
Identifieur interne : 000260 ( PubMed/Corpus ); précédent : 000259; suivant : 000261Efficacy and safety of prostate vaporesection using a 120-W 2-μm continuous-wave Tm:YAG laser (RevoLix 2) in patients on continuous oral anticoagulant or antiplatelet therapy.
Auteurs : Luciano Macchione ; Giuseppe Mucciardi ; Alessandro Gali' ; Antonina Di Benedetto ; Salvatore Butticè ; Carlo MagnoSource :
- International urology and nephrology [ 1573-2584 ] ; 2013.
English descriptors
- KwdEn :
- Administration, Oral, Aged, Anticoagulants (administration & dosage), Hematuria (etiology), Humans, Lasers, Solid-State (adverse effects), Lasers, Solid-State (therapeutic use), Length of Stay, Male, Middle Aged, Operative Time, Platelet Aggregation Inhibitors (therapeutic use), Prostatic Hyperplasia (blood), Prostatic Hyperplasia (complications), Prostatic Hyperplasia (surgery), Prostatism (etiology), Prostatism (surgery), Quality of Life, Retrospective Studies, Severity of Illness Index, Sodium (blood), Urinary Catheterization.
- MESH :
- chemical , administration & dosage : Anticoagulants.
- adverse effects : Lasers, Solid-State.
- blood : Prostatic Hyperplasia, Sodium.
- complications : Prostatic Hyperplasia.
- etiology : Hematuria, Prostatism.
- surgery : Prostatic Hyperplasia, Prostatism.
- therapeutic use : Lasers, Solid-State, Platelet Aggregation Inhibitors.
- Administration, Oral, Aged, Humans, Length of Stay, Male, Middle Aged, Operative Time, Quality of Life, Retrospective Studies, Severity of Illness Index, Urinary Catheterization.
Abstract
The aim of our current study was to demonstrate the efficacy and safety of vaporesection using a 120-W Tm:YAG laser (Revolix Duo) in patients with BPH receiving systemic anticoagulation or antiplatelet therapy. Between April 2010 and November 2011, a total of 76 patients using oral antiplatelet or anticoagulant (OA) agents affected by LUTS for BPH were underwent thulium vaporesection of the prostate (ThuVARP) using a 120-W 2-μm CW Tm:YAG laser and evaluated at 3- and 6-month follow-up. Of these, in 41 patients (group A) was performed vaporesection while receiving OA therapy. In 35 patients (group B), OA agents were discontinued 10 days before surgery. There were no significant differences in average vaporesection times, catheterization time, or hospital stay. There was no significant change in serum sodium level before and immediately after vaporesection in either group. Significant improvements compared to baseline were observed at each postoperative assessment in both groups for Qmax, PVR, IPSS, and QoL. More specifically, the IPSS score improved from 21.7 at baseline to 5.2 at 6 months in group A and from 20.7 to 4.5 in group B. At 6 months, Qmax increased 226 and 190 % for the 2 groups, respectively. The PVR decreased from 119 at baseline to 11 mL at 6 months in group A and from 125 to 11 mL in group B. ThuVARP is a safe and efficient procedure for patients with BPH, refractory to pharmacotherapy, who require active antiplatelet or anticoagulant therapy.
DOI: 10.1007/s11255-013-0487-y
PubMed: 23892531
Links to Exploration step
pubmed:23892531Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy and safety of prostate vaporesection using a 120-W 2-μm continuous-wave Tm:YAG laser (RevoLix 2) in patients on continuous oral anticoagulant or antiplatelet therapy.</title><author><name sortKey="Macchione, Luciano" sort="Macchione, Luciano" uniqKey="Macchione L" first="Luciano" last="Macchione">Luciano Macchione</name><affiliation><nlm:affiliation>Department of Urology, University of Messina, Via Consolare valeria 1, 98126, Messina, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Mucciardi, Giuseppe" sort="Mucciardi, Giuseppe" uniqKey="Mucciardi G" first="Giuseppe" last="Mucciardi">Giuseppe Mucciardi</name></author><author><name sortKey="Gali, Alessandro" sort="Gali, Alessandro" uniqKey="Gali A" first="Alessandro" last="Gali'">Alessandro Gali'</name></author><author><name sortKey="Di Benedetto, Antonina" sort="Di Benedetto, Antonina" uniqKey="Di Benedetto A" first="Antonina" last="Di Benedetto">Antonina Di Benedetto</name></author><author><name sortKey="Buttice, Salvatore" sort="Buttice, Salvatore" uniqKey="Buttice S" first="Salvatore" last="Butticè">Salvatore Butticè</name></author><author><name sortKey="Magno, Carlo" sort="Magno, Carlo" uniqKey="Magno C" first="Carlo" last="Magno">Carlo Magno</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="doi">10.1007/s11255-013-0487-y</idno><idno type="RBID">pubmed:23892531</idno><idno type="pmid">23892531</idno><idno type="wicri:Area/PubMed/Corpus">000260</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000260</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Efficacy and safety of prostate vaporesection using a 120-W 2-μm continuous-wave Tm:YAG laser (RevoLix 2) in patients on continuous oral anticoagulant or antiplatelet therapy.</title><author><name sortKey="Macchione, Luciano" sort="Macchione, Luciano" uniqKey="Macchione L" first="Luciano" last="Macchione">Luciano Macchione</name><affiliation><nlm:affiliation>Department of Urology, University of Messina, Via Consolare valeria 1, 98126, Messina, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Mucciardi, Giuseppe" sort="Mucciardi, Giuseppe" uniqKey="Mucciardi G" first="Giuseppe" last="Mucciardi">Giuseppe Mucciardi</name></author><author><name sortKey="Gali, Alessandro" sort="Gali, Alessandro" uniqKey="Gali A" first="Alessandro" last="Gali'">Alessandro Gali'</name></author><author><name sortKey="Di Benedetto, Antonina" sort="Di Benedetto, Antonina" uniqKey="Di Benedetto A" first="Antonina" last="Di Benedetto">Antonina Di Benedetto</name></author><author><name sortKey="Buttice, Salvatore" sort="Buttice, Salvatore" uniqKey="Buttice S" first="Salvatore" last="Butticè">Salvatore Butticè</name></author><author><name sortKey="Magno, Carlo" sort="Magno, Carlo" uniqKey="Magno C" first="Carlo" last="Magno">Carlo Magno</name></author></analytic><series><title level="j">International urology and nephrology</title><idno type="eISSN">1573-2584</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term><term>Aged</term><term>Anticoagulants (administration & dosage)</term><term>Hematuria (etiology)</term><term>Humans</term><term>Lasers, Solid-State (adverse effects)</term><term>Lasers, Solid-State (therapeutic use)</term><term>Length of Stay</term><term>Male</term><term>Middle Aged</term><term>Operative Time</term><term>Platelet Aggregation Inhibitors (therapeutic use)</term><term>Prostatic Hyperplasia (blood)</term><term>Prostatic Hyperplasia (complications)</term><term>Prostatic Hyperplasia (surgery)</term><term>Prostatism (etiology)</term><term>Prostatism (surgery)</term><term>Quality of Life</term><term>Retrospective Studies</term><term>Severity of Illness Index</term><term>Sodium (blood)</term><term>Urinary Catheterization</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anticoagulants</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Lasers, Solid-State</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Prostatic Hyperplasia</term><term>Sodium</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Prostatic Hyperplasia</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Hematuria</term><term>Prostatism</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Prostatic Hyperplasia</term><term>Prostatism</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Lasers, Solid-State</term><term>Platelet Aggregation Inhibitors</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term><term>Aged</term><term>Humans</term><term>Length of Stay</term><term>Male</term><term>Middle Aged</term><term>Operative Time</term><term>Quality of Life</term><term>Retrospective Studies</term><term>Severity of Illness Index</term><term>Urinary Catheterization</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aim of our current study was to demonstrate the efficacy and safety of vaporesection using a 120-W Tm:YAG laser (Revolix Duo) in patients with BPH receiving systemic anticoagulation or antiplatelet therapy. Between April 2010 and November 2011, a total of 76 patients using oral antiplatelet or anticoagulant (OA) agents affected by LUTS for BPH were underwent thulium vaporesection of the prostate (ThuVARP) using a 120-W 2-μm CW Tm:YAG laser and evaluated at 3- and 6-month follow-up. Of these, in 41 patients (group A) was performed vaporesection while receiving OA therapy. In 35 patients (group B), OA agents were discontinued 10 days before surgery. There were no significant differences in average vaporesection times, catheterization time, or hospital stay. There was no significant change in serum sodium level before and immediately after vaporesection in either group. Significant improvements compared to baseline were observed at each postoperative assessment in both groups for Qmax, PVR, IPSS, and QoL. More specifically, the IPSS score improved from 21.7 at baseline to 5.2 at 6 months in group A and from 20.7 to 4.5 in group B. At 6 months, Qmax increased 226 and 190 % for the 2 groups, respectively. The PVR decreased from 119 at baseline to 11 mL at 6 months in group A and from 125 to 11 mL in group B. ThuVARP is a safe and efficient procedure for patients with BPH, refractory to pharmacotherapy, who require active antiplatelet or anticoagulant therapy.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">23892531</PMID><DateCreated><Year>2013</Year><Month>12</Month><Day>02</Day></DateCreated><DateCompleted><Year>2014</Year><Month>07</Month><Day>31</Day></DateCompleted><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2584</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>6</Issue><PubDate><Year>2013</Year><Month>Dec</Month></PubDate></JournalIssue><Title>International urology and nephrology</Title><ISOAbbreviation>Int Urol Nephrol</ISOAbbreviation></Journal><ArticleTitle>Efficacy and safety of prostate vaporesection using a 120-W 2-μm continuous-wave Tm:YAG laser (RevoLix 2) in patients on continuous oral anticoagulant or antiplatelet therapy.</ArticleTitle><Pagination><MedlinePgn>1545-51</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11255-013-0487-y</ELocationID><Abstract><AbstractText>The aim of our current study was to demonstrate the efficacy and safety of vaporesection using a 120-W Tm:YAG laser (Revolix Duo) in patients with BPH receiving systemic anticoagulation or antiplatelet therapy. Between April 2010 and November 2011, a total of 76 patients using oral antiplatelet or anticoagulant (OA) agents affected by LUTS for BPH were underwent thulium vaporesection of the prostate (ThuVARP) using a 120-W 2-μm CW Tm:YAG laser and evaluated at 3- and 6-month follow-up. Of these, in 41 patients (group A) was performed vaporesection while receiving OA therapy. In 35 patients (group B), OA agents were discontinued 10 days before surgery. There were no significant differences in average vaporesection times, catheterization time, or hospital stay. There was no significant change in serum sodium level before and immediately after vaporesection in either group. Significant improvements compared to baseline were observed at each postoperative assessment in both groups for Qmax, PVR, IPSS, and QoL. More specifically, the IPSS score improved from 21.7 at baseline to 5.2 at 6 months in group A and from 20.7 to 4.5 in group B. At 6 months, Qmax increased 226 and 190 % for the 2 groups, respectively. The PVR decreased from 119 at baseline to 11 mL at 6 months in group A and from 125 to 11 mL in group B. ThuVARP is a safe and efficient procedure for patients with BPH, refractory to pharmacotherapy, who require active antiplatelet or anticoagulant therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Macchione</LastName><ForeName>Luciano</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Messina, Via Consolare valeria 1, 98126, Messina, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mucciardi</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Gali'</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Di Benedetto</LastName><ForeName>Antonina</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Butticè</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Magno</LastName><ForeName>Carlo</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>07</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int Urol Nephrol</MedlineTA><NlmUniqueID>0262521</NlmUniqueID><ISSNLinking>0301-1623</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010975">Platelet Aggregation Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>9NEZ333N27</RegistryNumber><NameOfSubstance UI="D012964">Sodium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000284">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000925">Anticoagulants</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006417">Hematuria</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D053844">Lasers, Solid-State</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007902">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D061646">Operative Time</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010975">Platelet Aggregation Inhibitors</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011470">Prostatic Hyperplasia</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000601">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D053448">Prostatism</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011788">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012964">Sodium</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014546">Urinary Catheterization</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2013</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1007/s11255-013-0487-y</ArticleId><ArticleId IdType="pubmed">23892531</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Terre/explor/ThuliumV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000260 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000260 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Terre
|area= ThuliumV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:23892531
|texte= Efficacy and safety of prostate vaporesection using a 120-W 2-μm continuous-wave Tm:YAG laser (RevoLix 2) in patients on continuous oral anticoagulant or antiplatelet therapy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:23892531" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ThuliumV1
| This area was generated with Dilib version V0.6.21. |  |